CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

BACKGROUND: Despite recent advances in immunotherapy, many patients with non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICI). Resistance to ICI may be driven by suboptimal priming of antitumor T lymphocytes due to poor antigen presentation as well as their exclusi...

Descripción completa

Detalles Bibliográficos
Autores principales: Salehi-Rad, Ramin, Lim, Raymond J, Du, Yushen, Tran, Linh M, Li, Rui, Ong, Stephanie L, Ling Huang, Zi, Dumitras, Camelia, Zhang, Tianhao, Park, Stacy J, Crosson, William, Kahangi, Bitta, Abascal, Jensen, Seet, Christopher, Oh, Michael, Shabihkhani, Maryam, Paul, Manash, Krysan, Kostyantyn, Lisberg, Aaron E, Garon, Edward B, Liu, Bin, Dubinett, Steven M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510892/
https://www.ncbi.nlm.nih.gov/pubmed/37730274
http://dx.doi.org/10.1136/jitc-2023-006896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510892/
https://www.ncbi.nlm.nih.gov/pubmed/37730274
http://dx.doi.org/10.1136/jitc-2023-006896

Ejemplares similares